Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Captain Jack who wrote (1280)	2/7/1999 10:12:00 PM
From: Alex Glavinos	Read Replies (1) \| Respond to of 1510

John, I believe WLA will continue to support IRC's remune program as long as results are positive. I base my thoughts after reading the following post on the Yahoo thread: Excerpt from Jan. 26 news release. For those that didn't read it. URL included. Wild said another very important product in Agouron's pipeline is Remune, a killed and altered HIV virus being tested in Phase III trials to see if it can boost the immune systems of patients infected by the virus. ''Remune's potential is enormous because if it works, it could be added to the drug regimens of every AIDS patient,'' Wild said. biz.yahoo.com